NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy (NCT06403267)
A Multicentre, Prospective, Randomized, Open Label, Blinded-Endpoint, Placebo-controlled, Single-dose Trial to Determine the Efficacy and Safety of NoNO-42 in Participants With Acute Ischemic Stroke Selected for Thrombolysis With or Without Endovascular Thrombectomy (ACT-42 Trial)
🩺 Plain-English Summary (8th-Grade Level)
ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632). This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial. A total of up to 600 male and female participants aged ≥ 18 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 4.5 hours of stroke onset/last known well.
Who can join: Review the eligibility criteria below.
Location: University of Calgary - Foothills Medical Centre — Calgary, Alberta
Age range: 18 Years to 90 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- University of Calgary - Foothills Medical Centre — Calgary, Alberta
- University of Alberta Hospital — Edmonton, Alberta
- Vancouver General Hospital — Vancouver, British Columbia
- University of Manitoba — Winnipeg, Manitoba
- Hamilton General Hospital — Hamilton, Ontario
- Ottawa Hospital Research Institute — Ottawa, Ontario
- Sunnybrook Health Sciences Centre — Toronto, Ontario
- Unity Health Toronto, St. Michael's Hospital — Toronto, Ontario
- Royal University Hospital — Saskatoon, Saskatchewan
📞 Contact the Study Coordinator
Phone: (416) 583-1687
Email: mtymianski@nonoinc.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Ischemic Stroke
- EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE-MeVO Trial) — Little Rock, Arkansas
- PET Perfusion Imaging Techniques and Comparing Them to CT Perfusion Imaging in Stroke — Edmonton, Alberta
- An EFS to Evaluate the CGuard Prime™ Carotid Stent in Acute Ischemic Stroke — Buffalo, New York
- Safety Of A Second Dose Of Tenecteplase In Selected Acute Ischemic Stroke Patients Not Responding To The First Dose — Houston, Texas
- Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke — Richmond, British Columbia
- Quelling of Excitotoxicity in Acute Stroke With Ketamine — Wynnewood, Pennsylvania
Explore by condition: All Acute Ischemic Stroke clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.